Dr. Xinping Song Explained Scope and Limitations of Prostate Specific Antigen Test at Changsha Conference

Dr. Xinping Song, an eminent prostate cancer researcher from China who runs his own clinic, recently revealed their research findings on the Prostate Specific Antigen Test in Changsha.

Changsha, China - August 3, 2017 /PressReleaseAgency/ —

Prostate Specific Antigen (PSA) is a specific protein of about 34,000 molecules compounded and secreted by prostatic epithelial cells to the seminal fluid and one of the main components of seminal plasma. Dr. Xinping Song, a prostate cancer researcher and physician from China, recently introduced the test at a press conference and announced talked about the scope and limitations of the test at length.

“PSA can decompose the colloidal protein in the seminal fluid, and it plays a role in diluting the seminal fluid. If PSA secretion is too low, the liquefaction time of seminal fluid will increase, causing male infertility. Therefore, PSA is a normal physiological substance secreted by human prostatic acinus and epithelial cells of ducts. PSA is not a carcinogenic substance”, Dr. Song said.

“In a normal prostatic ductal system, there exists a vascular-epithelial barrier and prostate envelop barrier. These barriers prevent the PSA produced by the prostate epithelium from entering directly into the blood. Thus, a low concentration of serum PSA is maintained. A PSA less than 4.0 nanogram is considered normal”, he added.

According to Dr. Song, the inventor of the test, two factors closely related to the serum PSA concentration are the prostate vascular-epithelial barrier and prostate envelop barrier and the prostate epithelial secretion.

At the recently held press conference in Changsha, Dr. Song also said that the prostate vascular-epithelial barrier and prostate envelop barrier directly affect serum PSA levels. “Malignant and non-malignant pathological changes that damage the prostate vascular-epithelial barrier and prostate envelop barrier can cause serum PSA elevation”, he told the press.

One of the co-researchers from Dr. Song’s 3D Prostate Clinic in China said that prostate cancer often causes malignant pathological changes to occur.

“At the first and second clinical stages of prostate cancer, if the prostate cancer does not damage the prostate vascular-epithelial barrier or prostate envelop barrier, the serum PSA concentration will usually remain within the normal range or will not rise higher than 10 nanograms. At the third and fourth clinical stages of prostate cancer, the prostate damages the prostate vascular-epithelial barrier and prostate envelop barrier”, he said while explaining the finer details of the test.

“If the prostate cancer severely damages the prostate vascular-epithelial barrier and prostate envelop barrier, the barriers are slow to recover. Also, the reduction of the serum PSA concentration is slow or does not reduce continuously after the prostate cancer cells and tumors are effectively killed and cleared. Such are the cases in patients with damage barriers receiving the 3D Prostate Cancer Targeted Treatment. Thus, patients need to take oral medicines that can accelerate the mucosal epithelium grow, and repair the prostate vascular-epithelial barrier and prostate envelop barrier. And, then the serum PSA concentration can return to normal”, he said.

According to the co-researcher, who is also the spokesperson for Dr. Song’s 3D Prostate Clinic, non-malignant pathological changes include prostatitis, BPH, acute urinary retention, ejaculation, prostate massage, prostate biopsy, and trans-urethral resection of the prostate. If the non-malignant pathological changes have affected and damaged the prostate vascular-epithelial barrier and prostate envelop barrier, the changes can cause an increase in serum PSA concentration. “If the damage caused to the barriers is not severe, and the non-malignant lesions are broken down and cleared, then the barriers can recover quickly. The serum PSA concentration should gradually return to normal”, he underlined.

“For a prostate cancer patient, it is important to understand that PSA is not a cancer marker produced by the prostatic cancer cells. PSA is a normal physiological substance compounded and secreted by the prostatic epithelial cells to support the seminal fluid. The concentration of PSA compounded and secreted by the prostatic epithelial cells, is controlled by the endocrine hormones; especially androgens, estradiol, and prolactin”, he said.

The conference, which was attended by a section of the media and eminent cancer researchers, was held at a business conference venue in Changsha.

“The prostate contains abundant sexual hormone receptors. Any factor affecting the pituitary gland, adrenal gland, and testis axis that causes endocrine hormone disorder can affect serum PSA concentration. For example, factors causing the absolute or relative blood concentration of androgen, estradiol or prolactin increase can increase serum PSA concentration secreted by the prostatic epithelial cells. On the contrary, factors causing the absolute or relative blood concentration of androgen, estradiol or prolactin decrease can decrease serum PSA concentration secreted by the prostatic epithelial cells”, another co-researcher told the press.

Dr. Song warned that prostate specific antigen should not be used as the diagnostic criteria for prostate cancer. “Many clinical studies on prostate cancer indicate problems with the PSA test. These problems include false positive results and the over-diagnosis of prostate cancer. Also, when the PSA diagnostic result is positive, the patient often undergoes more examinations including prostate biopsy, which create complications and risks, such as, infection, bleeding, cancer cell spread from the needle track, and urinary incontinence. False positive cancer reports based on elevated PSA levels cause patients to receive unnecessary treatment resulting in many adverse side effects, pain, and suffering. Therefore, many scholars suggest PSA should not be used to screen for prostate cancer”, Dr. Song said.

“However, one should not disregard the PSA in prostate cancer screening. The PSA is an important secondary indicator. It can tell us if an unhealthy condition exists within the prostate. For the diagnosis of prostate cancer, the PSA should only be used as a secondary indicator. Primary indicators for prostate cancer include patient symptoms, physical examination, digital rectal examination, microscopic examination of the expressed prostate fluid, trans-rectal ultrasound, magnetic resonance imaging, microscopic examination of the expressed prostate fluid, and miRNA”, he signed off after delivering his cautionary speech.

Contact Info:
Name: Alisa Wang
Email: [email protected]
Organization: Dr. Song's 3D Urology and Prostate Clinic
Phone: 86-186-7321-6429

For more information, please visit http://www.3dprostatecure.com/

Source: PressReleaseAgency

Release ID: 224799